| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.098 | 0.008 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.009 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.01 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.093 | 0.02 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |